Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / HOLX - FDA OK's Hologic's Aptima HIV-1 Quant Dx assay for HIV diagnosis


HOLX - FDA OK's Hologic's Aptima HIV-1 Quant Dx assay for HIV diagnosis

The FDA has approved Hologic's (HOLX) diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring assay.The Aptima HIV-1 Quant Dx assay, a molecular diagnostic test that runs on the fully automated, sample-to-result Panther system is now the first dual-claim assay for both diagnosis and viral load monitoring in U.S. The assay utilizes a dual target approach against highly conserved regions in the HIV genome, designed to deliver reliable, consistent qualitative and quantitative results across HIV-1 groups and subtypes.The Aptima HIV-1 Quant Dx assay is also CE IVD-marked for both diagnostic and viral load monitoring claims.

For further details see:

FDA OK's Hologic's Aptima HIV-1 Quant Dx assay for HIV diagnosis
Stock Information

Company Name: Hologic Inc.
Stock Symbol: HOLX
Market: NASDAQ
Website: hologic.com

Menu

HOLX HOLX Quote HOLX Short HOLX News HOLX Articles HOLX Message Board
Get HOLX Alerts

News, Short Squeeze, Breakout and More Instantly...